

Th17 CELL MASTER TRANSCRIPTION FACTOR RORC2 REGULATES HIV GENE EXPRESSION AND LATENCY

Tomas Raul Wiche Salinas

*Centre de recherche du CHUM
Montreal, Québec, Canada*

This study tested RORC2 inhibitors provided by GSK and was funded by GSK/NeoMed

Introduction

BACKGROUND:

- HIV-DNA reservoirs persist in CCR6+ CD4+ T-cells from colon and blood of ART-treated PLWH

(Gosselin/Wiche Salinas et al., AIDS, 2017; Anderson et al., JID, 2020)

- CCR6+ Th17 cells are enriched in HIV permissiveness factors and lack intrinsic antiviral mechanisms

(Cleret-Buhot et al., Retrovirology, 2013; Planas et al., JCI insight 2017, Christensen-Quick et al., JVI 2016)

- Retinoic acid receptor-related orphan receptor 2 (RORC2): the master regulator of Th17 polarization


(Ivanov et al., Cell, 2006; Yang XO et al., Immunity, 2008)

HYPOTHESIS:

- RORC2 mediates the permissiveness of Th17 cells to HIV infection and sustains viral reservoir reactivation from latency and viral outgrowth





OBJECTIVE:

- To define mechanisms by which RORC2 regulates HIV replication in CD4+ T cells





Results - 1

1. RORC Reverse Agonists Inhibit HIV-1 Infection in Primary CD4+ T Cells







2. RORC2 is a Host Co-factor for HIV-1 Infection of CD4+ T Cells

A. RORC2 overexpression in Jurkat Cells




B. RORC2 silencing in primary CD4+ T cells





Results - 2

3. RORC2 Promotes HIV-1 Gene Expression




4. RORC2 Binds to the HIV-1 LTR (RORC2-myc ChIP)




Results - 3

5. CD4+ T Cells Expressing a CCR6+RORC2+ Th17 Phenotype Are Enriched In Integrated HIV-DNA In ART-Treated PLWH




6. RORC Antagonism Inhibits HIV-1 Outgrowth in CD4+ T Cells of ART-Treated and Untreated PLWH



Conclusions

- The Th17 cell master transcription factor RORC2 is critical host co-factor for HIV-1 replication
- RORC2 reverse agonists inhibited HIV-1 replication in primary CD4+ T cells in a dose-dependent manner
- RORC2 silencing inhibited HIV-1 infection in bulk memory and sorted CCR6+ CD4+ T cells
- RORC2 promoted HIV-1 gene expression
- Chromatin immune precipitation (ChIP) revealed that RORC2 binds to the HIV-1 promoter
- RORC2 reverse agonists potently reduced HIV-1 outgrowth in CD4+ T cells of ART-treated and untreated PLWH
- **Altogether, these results provide a new explanation why Th17 cells are highly susceptible to HIV-1 infection and point to RORC2 as a novel cell-specific target for HIV-1 therapy.**



Acknowledgements

CRCHUM

Laboratory of
Dr. Petronela Ancuta

Yuwei Zhang
Delphine Planas
Laurence Raymond Marchand
Debashree Chatterjee
Nicol Flores
Augustine Fert
Amélie Cattin
Etiene Moreira Gabriel
Christ Ngassaki-Yoka
Jonathan Dias

McGill University

Jean-Pierre Routy

IRCM

Éric A. Cohen

CHU-St Justine

Elie Haddad

University College London

Laboratory of

Dr. Ariberto Fassati

Daniele Sarnello
Alexander Zhyvoloup
Manivel Lodha
Kasia Karwacz
Sally Oxenford

GSK

Heather Madsen
David Irlbeck
David Favre

Flow Cytometry Platform

Dominique Gauchat
Philippe St Onge

NLC3 Platform

Olfa Debbeche

FRQ-S/AIDS and Infectious Diseases Network

Mario Legault

Participants for their gift of blood samples.

Faculté de médecine



Fonds de recherche
Santé

Québec

